Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome

Simple item page
dc.contributor.authorSezgin, Canfeza
dc.contributor.authorÖzdemir, Necmettin
dc.contributor.authorGöker, Erdem
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi.tr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid6602587152tr_TR
dc.date.accessioned2022-10-25T06:04:05Z
dc.date.available2022-10-25T06:04:05Z
dc.date.issued2007-01
dc.description.abstractObjective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes. Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 Mg/m(2)/d) in patients with anthra-cycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment. Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP. Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.en_US
dc.identifier.citationSezgin, C. vd. (2007). "Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome". Southern Medical Journal, 100(1), 27-32.en_US
dc.identifier.endpage32tr_TR
dc.identifier.issn0038-4348
dc.identifier.issn1541-8243
dc.identifier.issue1tr_TR
dc.identifier.pubmed17269522tr_TR
dc.identifier.scopus2-s2.0-33846247078tr_TR
dc.identifier.startpage27tr_TR
dc.identifier.urihttps://doi.org/10.1097/01.smj.0000252968.87824.19
dc.identifier.urihttps://sma.org/southern-medical-journal/article/efficacy-of-lower-dose-capecitabine-in-patients-with-metastatic-breast-cancer-and-factors-influencing-therapeutic-response-and-outcome/
dc.identifier.urihttp://hdl.handle.net/11452/29196
dc.identifier.volume100tr_TR
dc.identifier.wos000246777300009tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalSouthern Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGeneral & internal medicineen_US
dc.subjectCapecitabineen_US
dc.subjectMetastatic breast canceren_US
dc.subjectMulticenter Phase IIen_US
dc.subjectCarcinomaen_US
dc.subjectAmplificationen_US
dc.subjectSafetyen_US
dc.subject.emtreeTamoxifenen_US
dc.subject.emtreeAnthracyclineen_US
dc.subject.emtreeCapecitabineen_US
dc.subject.emtreeCyclophosphamideen_US
dc.subject.emtreeFluorouracilen_US
dc.subject.emtreeMethotrexateen_US
dc.subject.emtreeConjunctivitisen_US
dc.subject.emtreeTaxane derivativeen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeAnorexiaen_US
dc.subject.emtreeAntineoplastic activityen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBreast canceren_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug responseen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeDyspepsiaen_US
dc.subject.emtreeFatigueen_US
dc.subject.emtreeHand foot syndromeen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeMultivariate analysisen_US
dc.subject.emtreeInfectionen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeSide effecten_US
dc.subject.emtreeToxic hepatitisen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeUnivariate analysisen_US
dc.subject.meshDeoxycytidineen_US
dc.subject.meshAdministration, oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntimetabolites, antineoplasticen_US
dc.subject.meshBreast neoplasmsen_US
dc.subject.meshDisease progressionen_US
dc.subject.meshNeoplasm metastasisen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracilen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshProdrugsen_US
dc.subject.meshSurvival rateen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusCapecitabine; Hand Foot Syndrome; Vinorelbine Tartrateen_US
dc.subject.wosMedicine, general & internalen_US
dc.titleEfficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcomeen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus